

IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF INDIANA
INDIANAPOLIS DIVISION

ELI LILLY AND COMPANY,)
)
Plaintiff,)
v.) Civil Action No. 1:16-cv-308
)
DR. REDDY'S LABORATORIES, LTD. and)
DR. REDDY'S LABORATORIES, INC.,)
)
Defendants.)

COMPLAINT

Plaintiff Eli Lilly and Company ("Lilly"), by its attorneys, hereby alleges as follows:

NATURE OF THE ACTION

1. This is an action for patent infringement under the patent laws of the United States, Title 35, United States Code, that arises out of the filing by defendant Dr. Reddy's Laboratories, Inc. on behalf of defendant Dr. Reddy's Laboratories, Ltd. (collectively, "DRL") of a New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") seeking approval to manufacture and sell its Pemetrexed for Injection 100 mg/vial and 500 mg/vial products ("DRL's NDA Products") prior to the expiration of U.S. Patent No. 7,772,209 ("the '209 patent"). DRL notified Lilly that it had submitted to the FDA NDA No. 208297 for DRL's NDA Products by letter dated December 22, 2015 ("DRL's Notice Letter" or "Notice Letter"). Upon information and belief, DRL's NDA Products will be marketed as competing products to ALIMTA[®], a chemotherapy agent developed and distributed by Lilly and used for the treatment of various types of cancer.

PARTIES

2. Lilly is a corporation organized and existing under the laws of the State of Indiana, having its corporate offices and place of business at Lilly Corporate Center, Indianapolis, Indiana 46285.

3. Upon information and belief, Dr. Reddy's Laboratories, Ltd. is a corporation organized and existing under the laws of India, having a place of business at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, India 500034.

4. Upon information and belief, Dr. Reddy's Laboratories, Inc. is a corporation organized and existing under the laws of the State of New Jersey, having a place of business at 107 College Road East, Princeton, New Jersey 08540. Upon information and belief, Dr. Reddy's Laboratories, Inc. is in the business of manufacturing, marketing, and selling generic drug products.

5. Upon information and belief, Dr. Reddy's Laboratories, Inc. is a wholly-owned subsidiary of Dr. Reddy's Laboratories, Ltd. Upon information and belief, Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. are agents and/or alter-egos of one another, operate in concert as integrated parts of the same business group, and enter or have entered into agreements with each other that are nearer than arm's length, including with respect to the manufacture, importation, marketing, sale, and distribution of DRL's NDA Products.

JURISDICTION AND VENUE

6. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

7. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400(b).

8. Upon information and belief, Dr. Reddy's Laboratories, Ltd. is a generic pharmaceutical company in India engaged in developing, manufacturing, marketing, selling, and distributing a broad range of pharmaceutical products globally. Upon information and belief, a substantial number of these products are marketed throughout the United States, including in the State of Indiana. Upon information and belief, Dr. Reddy's Laboratories, Ltd. operates its manufacturing, marketing, sales, and distribution infrastructure in the United States through Dr. Reddy's Laboratories, Inc. as a vertically-integrated company.

9. Upon information and belief, Dr. Reddy's Laboratories, Inc. performs functions relating to Dr. Reddy's Laboratories, Ltd., including manufacturing, marketing, and sales. Lee Banks, Esq., who is listed in DRL's Notice Letter as the Vice President, Intellectual Property of Dr. Reddy's Laboratories, Inc., is designated as the agent of Dr. Reddy's Laboratories, Ltd. for service of process with respect to this litigation. Upon information and belief, Dr. Reddy's Laboratories, Inc. participated with Dr. Reddy's Laboratories, Ltd. in the preparation, review, and/or submission of NDA No. 208297.

10. Upon information and belief, Dr. Reddy's Laboratories, Inc. is engaged in the manufacturing, marketing, and sale of generic pharmaceutical products for the U.S. prescription drug market on behalf of Dr. Reddy's Laboratories, Ltd. Upon information and belief, Dr. Reddy's Laboratories, Ltd. provides Dr. Reddy's Laboratories, Inc. with products for sale in the United States. Upon information and belief, those products are then marketed, sold, and distributed to oncologists, clinics, and hospitals throughout the United States, including in Indiana, as well as to wholesalers, who sell, with Dr. Reddy's Laboratories, Ltd.'s knowledge, Dr. Reddy's Laboratories Ltd.'s products, including in Indiana. Upon information and belief,

Dr. Reddy's Laboratories, Inc. or its affiliates will distribute DRL's NDA Products in the United States, including in Indiana, upon approval of NDA No. 208297.

11. Upon information and belief, DRL has previously used the process contemplated by the Food, Drug, and Cosmetic Act (the "FDCA"), 21 U.S.C. § 355(b) and the Drug Price Competition Term Restoration Act of 1984, 21. U.S.C. § 355(j) (the "Hatch-Waxman Act"), to challenge branded pharmaceutical companies' patents by filing a certification of the type described in Section 505(b)(2)(A)(iv) or 505(j)(2)(A)(vii)(IV), serving a notice letter on those companies, and engaging in patent litigation arising from the processes contemplated by those acts. Upon information and belief, as of March 31, 2015, DRL had cumulative filings of 735 Drug Master Files and 220 Abbreviated New Drug Applications ("ANDAs"), of which 68 were pending approval.

12. Upon information and belief, DRL has availed itself of the legal protections of the state of Indiana by filing claims or counterclaims affirmatively seeking relief in other prior actions in this Court.

13. Upon information and belief, with knowledge of the processes described in the FDCA and the Hatch-Waxman Act, DRL directed its Notice Letter to Lilly, an entity incorporated in Indiana, at its corporate headquarters in Indiana, and alleged in the Notice Letter the invalidity, unenforceability, and/or non-infringement of Lilly's '209 patent. Upon information and belief, DRL deliberately challenged Lilly's patent rights, and knew when it did so that it was triggering a forty-five-day period for Lilly to bring an action for patent infringement under the FDCA. Moreover, upon information and belief, DRL knew that other FDCA and/or Hatch-Waxman Act infringement actions relating to the '209 patent had been brought and litigated in Indiana.

14. Because Lilly is incorporated and has its principal place of business in Indiana, the injury and consequences of DRL's filing of NDA No. 208297, challenging Lilly's patent rights, are suffered in Indiana. Upon information and belief, DRL knew that it was deliberately challenging the patent rights of an Indiana entity and seeking to challenge intellectual property held in Indiana and that the effects of any successful challenge of the '209 patent would be felt by Lilly in Indiana.

15. Upon information and belief, if NDA No. 208297 is approved, DRL will directly or indirectly market and/or sell DRL's NDA Products within the United States, including in Indiana, consistent with DRL's practices for the marketing and distribution of other pharmaceutical products on its own or through its affiliates. Upon information and belief, DRL and/or its affiliates regularly do business in Indiana, and their practices with other pharmaceutical products have involved the distribution of DRL products, directly or indirectly, throughout the United States, including in Indiana. Upon information and belief, DRL's pharmaceutical products are used and/or consumed within and throughout the United States, including Indiana.

16. Upon information and belief, DRL and its affiliates derive substantial revenue from pharmaceutical products that are used and/or consumed within Indiana, and which are manufactured by DRL or its affiliates and/or for which DRL is the named applicant on approved NDAs or ANDAs. Upon information and belief, various products for which DRL, or its affiliates, is the named applicant on approved NDAs and ANDAs are available at pharmacies in Indiana.

17. Upon information and belief, if NDA No. 208297 is approved, DRL's NDA Products, under the direction and control of physicians practicing in Indiana, will be

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.